Our review confirms the usefulness of long-term pharmacological treatments for PD and GAD and suggests that they can provide further improvement over that obtained during short-term therapy .
Paroxetine , escitalopram , and clonazepam can be effective for long-term treatment of PD .
Pregabalin and quetiapine can be effective for long-term treatment of GAD , while preliminary suggestions emerged for agomelatine and vortioxetine .
We did not find any evidence for determining the optimal length and /or dosage of medications to minimize the relapse risk .
Many aspects of long-term pharmacological treatments for  anxiety disorders ( AnxDs ) are still debated .
We undertook an up date d systematic review of long-term pharmacological studies on panic disorder ( PD ) , generalized anxiety disorder ( GAD ) , and social anxiety disorder ( SAD ) .
Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
Background We evaluated the effects of once-daily extended-release quetiapine fumarate ( quetiapine XR ) on patient-reported outcomes in generalized anxiety disorder ( GAD ) . Methods This is a report of a pooled analysis from three acute 8-week , r and omized , placebocontrolled , fixed-dose ( 50 , 150 , 300 mg/day ) studies and a 52-week maintenance flexible dose ( 50–300 mg/day ) study of quetiapine XR monotherapy in patients with GAD .  Quality of Life Enjoyment and Satisfaction Question naire Short Form ( Q-LES-Q-SF ) percent maximum total scores ( items 1–14 ) , item 15 ( “ satisfaction with medication ” ) , item 16 ( “ overall life satisfaction ” ) , and Pittsburgh Sleep Quality Index ( PSQI ) global scores are reported . Sheehan Disability Scale ( SDS ) total scores were also assessed ( maintenance study only ) . Results The acute studies showed significant improvements at week 8 in Q-LES-Q-SF percent maximum total score  with quetiapine XR 150 mg/day ( P < 0.001 ) and item 16  with quetiapine XR 50 ( P < 0.05 ) and 150 mg/day ( P < 0.001 ) versus placebo ; PSQI global scores significantly improved with quetiapine XR 50 , 150 , and 300 mg/day versus placebo ( P < 0.001 ) . The maintenance study showed significant benefits versus placebo with quetiapine XR 50–300 mg/day in Q-LES-Q-SF percent total score , item 15 and item 16 scores , PSQI global score , and SDS total score . Conclusion Quetiapine XR 150 mg/day ( acute studies ) and 50–300 mg/day ( maintenance study ) improved quality of life , overall functioning , and sleep quality in patients with GAD
Our review confirms the usefulness of long-term pharmacological treatments for PD and GAD and suggests that they can provide further improvement over that obtained during short-term therapy .
Paroxetine , escitalopram , and clonazepam can be effective for long-term treatment of PD .
Pregabalin and quetiapine can be effective for long-term treatment of GAD , while preliminary suggestions emerged for agomelatine and vortioxetine .
We did not find any evidence for determining the optimal length and /or dosage of medications to minimize the relapse risk .
Many aspects of long-term pharmacological treatments for  anxiety disorders ( AnxDs ) are still debated .
We undertook an up date d systematic review of long-term pharmacological studies on panic disorder ( PD ) , generalized anxiety disorder ( GAD ) , and social anxiety disorder ( SAD ) .